UK’s MRC invests in research into hard-to-treat cancers 18 Sep 2023

UK Research and Innovation’s (UKRI) Medical Research Council (MRC) is investing £2 million to support research into cancers with poor survival rates. These include studies into cancers of the brain, lung and oesophagus.

The funding will be divided equally between four research innovation teams. Their projects were selected following a two-day ‘sandpit’ event where teams from different scientific disciplines collaborated to develop new ideas in prevention, diagnosis and treatment.

The four projects will be led by Imperial College London, University of Cardiff, Kings College London and the University of Manchester with The Christie NHS Foundation Trust.

Work will investigate techniques for removing brain cancer cells using a laser, use of a cryogel to deliver drugs to the site of a brain tumour removal, advancing AI to read lung scans and predict treatment-resistant cancer, as well as developing nanoparticle therapeutics for oesophageal cancer.

If you are developing an innovative therapy and need expert help to take it from the lab to commercialisation, contact PMC via hello@pharmamedic.co or T: +44 (0) 208 168 1668.